51.8 F
New York
Monday, October 3, 2022

Date:

Share:

New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report

Related Articles

Menlo Park, CA, September 21, 2022 –(PR.com)– Life Science Strategy Group (LSSG), the leading strategic consulting firm to the CRO, CDMO and Biopharmaceutical industries, is pleased to announce the launch of its new syndicated report, “Decentralized Clinical Trial (DCT) Strategies to Enhance Patient Satisfaction and Future Participation.” This landmark study of 360 clinical trial participants and 440 non-participants in the US and Europe demonstrates that convenience and flexibility is preferred. The analysis also shows that while in-person interaction with physicians remains important, less travel-focused clinical trials elements will drive clinical trial participation.

As utilization of decentralized clinical trial (DCT) strategies continues to grow following the COVID-19 pandemic, large CROs including IQVIA, Labcorp, Parexel, ICON, Thermo Fisher/PPD, and others continue to invest in remote and in-home capabilities. The market…

Read more…

Popular Articles